Docetaxel in Treating Older Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase II Trial Assessing the Impact on Instrumental and Daily Living Autonomy of a Chemotherapy Regimen With Bi-Weekly Docetaxel in the Treatment of Metastatic or Locally Advanced Non-Small Cell Lung Cancer in Patients Over the Age of 70
Sponsor: UNICANCER
Listed as NCT00227708, this PHASE2 trial focuses on Lung Cancer and remains completed. Sponsored by UNICANCER, it has been updated 6 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Jun 2018 — Mar 2020 [monthly]
Unknown Status PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Jun 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- UNICANCER
For direct contact, visit the study record on ClinicalTrials.gov .